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INTRODUCTION
Low back pain (LBP) is a pervasive problem impacting health systems across the world.
In the United States, chronic LBP impacts up to 40% of Americans and results in excessive financial strain on the healthcare budget, estimated at up to $100 billion annually.1
Furthermore, treatment results are often disappointing, with the traditional pathway of
conservative measures, narcotic pain medication, and surgical decompression and/or
fusion leading to both patient and provider frustration, complications, and diminished
patient productivity and quality of life. This has naturally led to questions from policymakers regarding the utility of healthcare dollars spent on back pain. In this milieu, a
variety of neuromodulation techniques have found a niche in the management of this
patient population, with indications commonly quoted including failed back surgery
syndrome (FBSS), chronic neuropathic pain, and complex regional pain syndrome
(CRPS), among others.1,2 From its inception on the basis of Melzak and Wall’s gate
theory³, to its first human trial in the 1960s,⁴ and to the modern era, spinal cord
stimulation has undergone a series of innovations that have expanded indications and
improved patient outcomes. The goal of this study is to summarize the most important
clinical trials involving both traditional SCS and newer stimulation paradigms to provide
an overview of the current state of affairs of this rapidly-growing field.

METHODS
We performed a PubMed literature search utilizing the following terms: SCS, spinal
cord stimulation, neuromodulation, high frequency stimulation, paresthesia free,
HF10, failed back surgery syndrome, and chronic pain. Only English language articles
were reviewed. All prospective, randomized controlled trials pertaining to the use of
neuromodulation in the treatment of chronic back and limb pain were included. The
data extraction was performed by three reviewers (JT, JH, CH), and reviewed by the
senior author (CW). The selected studies were analyzed, and relevant results were
summarized as follows.

RESULTS
Traditional, Low Frequency, Tonic SCS
Several landmark trials paved the way for the widespread use of spinal cord stimulation in the treatment of chronic back and limb pain. These early studies utilized low
frequency stimulation generally in the 40-100 Hz range delivered in a tonic manner,
producing paresthesias that overlap the areas where the patient experiences pain.
North et al5 randomized 51 FBSS patients with chronic lower limb pain with or without
back pain to initial treatment with a low frequency stimulator or re-operation. The
primary endpoint was “success”, defined as > 50% reported pain relief and patient
satisfaction with treatment at 2-years post-operatively or at last follow-up. Secondary
end points included treatment crossover, success at last follow-up, and improvement in medication use, daily activities, and neurologic status. At mean three-year
follow-up, “success” was achieved in a significantly higher proportion of patients
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randomized to SCS (47%) compared to
those randomized to reoperation. 5,6
These findings remained statistically
significant even after worst-case analysis
which assumed patients unavailable for
long-term follow-up in the SCS group
were all treatment failures. Further, a
significantly higher proportion of patients
in the reoperation arm crossed over to
SCS (54%) compared to only 21% of SCS
patients who elected to undergo reoperation. While patient reported functional
capacity didn’t reach a significant difference, SCS patients did require significantly
fewer opiate equivalents for pain control.
Kumar et al 7,8 followed this up with the
PROCESS study which randomized 100
FBSS patients with limb>back pain to
SCS with medical management (n=52)
or medical management alone (n=48).
The primary end point of the study was
defined as > 50% relief of leg pain, with
secondary end points including quality
of life, functional capacity as measured
by the Oswestry Disability Index (ODI),
patient satisfaction, and changes in pain
medication usage. At 6-month followup, the primary endpoint was achieved in
48% of SCS patients compared to 9% in
the medical management alone group.
The SCS group also reported significantly
greater quality of life, improvement in ODI,
treatment satisfaction, and reduced back
pain compared to medical management
alone. SCS patients were also more likely
to reduce drug intake based on morphine
equivalents as well as decrease use of nondrug therapies. Similar improvements were
maintained at 12 and 24 month follow-up
analyses.7,8

Paresthesia-Free SCS
As clinical experience with traditional,
paresthesia-based systems grew, interest
began to develop in creating new stimulation protocols that would generate
pain relief without the need for paresthesia overlap as a significant number
of patients found these sensations to be
uncomfortable, particularly when there

1

is significant postural variation which
can make certain daily activities, such
as driving, difficult or painful. Furthermore, traditional spinal cord stimulation,
while relatively successful at treating
appendicular neuropathic symptoms,
struggled with relief of more nociceptive
axial pain where adequate paresthesia
overlap is difficult to achieve. Given how
common low back pain is in the general
population, a more efficient means for
targeting this symptom complex was
needed. Buyten et al 9 prospectively
enrolled 82 patients with back pain with
or without associated leg pain in a trial
of high frequency, low amplitude, paresthesia free stimulation using the Nevro
device. The outcomes of interest were
VAS scores, ODI, sleep disturbances per
night, and patient satisfaction. The trial
to conversion rate was 88%. VAS back
and leg scores improved at 6 months, 8.4
to 2.7 for back and 5.4 to 1.4 for leg pain.
ODI improved by 17 points and patients
reported 2.4 fewer episodes of sleep
disturbance per night. Similar results
were obtained with HF10 therapy in
another prospective observational study
in patients with a primary complaint low
back pain, with back pain and leg pain
reduced by 61% and 58%, respectively,
based on VAS10. While promising, these
and other observational studies did not
provide a control group to compare
against. To that end, De Andres et al11
compared high frequency (10 kHz)
stimulation to conventional stimulation,
randomizing 55 patients with FBSS with
neuropathic back or leg pain. The results
suggested no significant difference at
one year, with both stimulation profiles
showing significant benefit compared
to baseline values.11 On the other hand,
North et al,12 in their pilot study randomizing patients with FBSS who had a
previously implanted, paresthesia-based
system with inadequate pain relief, noted
that pain relief via NRS and disability
via ODI were significantly improved
with 1 kHz stimulation. 12 Perruchoud
and colleagues 13 similarly randomized patients with chronic neuropathic
back and leg pain, previously stable on
a conventional SCS system, to periods
of sham and 5 kHz, subthreshold tonic
stimulation. The periods of sham and
5 kHz stimulation were separated by
a “washout” period during which the
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patients reverted to their traditional,
paresthesia-based pattern. The primary
outcome was the Patient’s Global
Impression of Change (PGIC), with
secondary outcomes including VAS
and the Euroqol questionnaire EQ-5D.
At the end of the study, the authors
noted no difference between sham and
high-frequency stimulation, with what
appeared to be a “period effect” in that
patients tended to respond more favorably to sham or 5 kHz stimulation based
purely on which was initiated first and
responded less favorably to whichever
pattern was tested second. However,
the comparison to baseline values is
confusing and again the use of previously
stabilized tSCS patients is a variable that
must be considered. The most robust
data in this field came from Kapural and
colleagues who explored the ability of
low amplitude, high frequency spinal
cord stimulation at 10 kHz to provide
durable relief of both axial and appendicular pain in the SENZA trial.14,15 In this
prospective, multicenter, randomized trial,
the investigators randomized 198 patients
with medically refractory back and leg
pain to either high frequency stimulation (HF10) or traditional low frequency,
paresthesia-dependent treatment (tSCS).
The primary endpoint was >50% reduction on the visual analog scale (VAS), with
secondary outcomes including opioid
use, functional disability as measured by
ODI, and percentage change from baseline back and leg symptoms. A total of
171 patients had positive trials and were
ultimately implanted (HF10, n=90; tSCS,
n = 81). At the initial 3-month evaluation, 84.5% of HF10 patients achieved
the primary endpoint for back pain,
compared to only 43.8% of tSCS patients.
Similarly, for leg pain HF10 success on the
primary endpoint was 83.1% compared
to 55.5% for tSCS. These values remained
similar at 12-month follow-up evaluation, with remission rates (VAS <2.5) for
back and leg pain approaching 67% for
HF10, compared to 35-40% for tSCS.
At 24-month evaluation, the difference
in primary endpoint success was still
maintained in favor of HF10 for both
back and leg pain (76.5% and 72.9%
respectively for HF10, compared to ~50%
for tSCS). Secondary outcome analysis
also favored HF10, with greater overall
percentage reduction of back and leg

pain compared to baseline, higher likelihood of achieving minimal disability on
ODI, and higher patient reported treatment satisfaction. Additionally, 11.3%
of patients in the tSCS group reported
uncomfortable paresthesias, with no
patients in the HF10 group reporting any
paresthesia-related issues.14,15
Despite accumulating clinical evidence
regarding the efficacy of high frequency
SCS, several questions remained. One such
issue is the impact of varying frequencies
and other stimulation parameters on treatment effect. One study16 prospectively
randomized a cohort of 24 patients into a
blinded crossover study, with each patient
experiencing 3 weeks at a time of sham
stimulation, and stimulation at 1200 Hz,
3030 Hz, and 5882 Hz. The devices were
programmed such that amplitude was
maintained slightly below threshold level,
unique to each patient and frequency.
The primary outcome was the reduction
of VAS back pain scores. Baseline VAS
was reported at 7.75, with improvement
to 4.83, 4.51, 4.57, and 3.22 for the trial
groups (sham, 1200 Hz, 3030 Hz, and
5882 Hz, respectively). All comparisons
to baseline were significant, but within
the treatment groups only 5882 Hz had a
significantly greater impact on outcome.
The authors argued that while designed
as a study on frequency, the impact of
pulse width on allowable amplitude
without generating paresthesia yielded
higher charger-per-second dosing with
higher frequency stimulation, which
may have played a role in the results.
The results also questioned to what
degree pain relief afforded by spinal cord
stimulation is a result of placebo, as at
the end of the study 12.5% of patients
preferred the sham stimulation protocol.
A similar study also explored the impact
of varying degrees of high-frequency
stimulation on treatment effect, noting
the unclear mechanism of HF10 and the
unclear impact of frequency on clinical
outcome. In this study, Thomson et al 17
randomized 21 patients with chronic
back>leg pain who had passed a trial of
10 kHz stimulation and were implanted
with permanent devices. Each patient
experienced four weeks of stimulation,
in random order, at 10 kHz, as well as 1-,
4-, and 7 kHz. At each frequency, pulse
width and amplitude were adjusted to
optimize therapy. The impact on the
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primary outcome, NRS for back, leg, and
overall pain, was similar between groups
with all frequency groups showing about
50% reduction in each category. There
were no between-group differences.
There was significantly less charge
delivered in the 1 kHz stimulation than in
the other three groups. Interestingly, the
calculated charge delivered per second
showed a non-linear relationship with
frequency, suggesting that frequency
modification in isolation may not deliver
appropriate symptom relief, highlighting
the importance of the interplay between
frequency, pulse width, and amplitude.
As interest in paresthesia-free stimulation
grows, other investigators are exploring
novel stimulation protocols. Burst stimulation, a technique based on short intervals
of high-frequency, low amplitude stimulation followed by periods of inactivity, is one
such protocol thought to work in at least
two mechanisms: 1) more closely mimic
neuronal firing in the central nervous
system with impacts on higher-order thalamo-cingulate pathways, and 2) provide
inhibition of Aδ and c fibers via subthreshold
antidromic Aβ activation with resultant
activation of inhibitory interneurons. De
Ridder et al18 performed an early trial with
this technology, randomizing 15 patients
undergoing a trial of spinal cord stimulation
to 7 days each of burst, tonic, and sham
stimulation. Primary endpoints included
VAS for back, limb, and general pain, with
secondary endpoints including the pain
vigilance and awareness scale (PVAQ), and
worst/best pain levels during a given trial
week. They noted that burst stimulation
did not induce more paresthesias than
sham stimulation. The primary outcome
measure showed significant improvements in back, limb, and general pain
comparing burst stimulation to placebo.
Because burst stimulation produced no
noticeable paresthesias, this marked the
first time in a randomized trial that spinal
cord stimulation could be proven better
than control/sham treatment, an important
landmark in SCS research. Not surprisingly,
tSCS showed significant improvement in
limb and general pain, but not back pain,
compared to placebo. Comparing burst
to tSCS, the mean change in back pain
favored burst (-3.8 on VAS compared to
-2.2), but this did not reach significance.
Limb pain between the two protocols
was the same (both -3.9 on VAS). General
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pain was significantly reduced with burst
therapy (-4.5 VAS) compared to tSCS
(-2.5). Regarding the PVAQ, tonic and
placebo stimulation showed no impact
on attention to pain or attention to
changes in pain, whereas burst stimulation
significantly improved these parameters,
suggesting an impact on affective and
attentional components of pain. Schu et al
19
compared high frequency stimulation to
a burst protocol, randomizing 20 patients
with FBSS and a previously implanted,
burst-capable system to separate, one
week periods of placebo stimulation, 500
Hz tonic stimulation, and burst stimulation
(5 pulses at 500 Hz, delivered 40 times
per second), with the primary outcome
of interest the impact on the numerical
rating scale (NRS) for pain intensity. Baseline values were obtained prior to entering
the protocol, with the device programmed
for standard, paresthesia-based stimulation. While burst stimulation was the only
pattern to significantly reduce the NRS
score, the magnitude of the treatment
effect was modest (5.6 at baseline, 4.7
for burst stimulation), and disability as
measured by ODI showed only a nonsignificant decrease. However, it is worth
reiterating that the “control” values in this
study were based on patients stabilized
on a paresthesia-based system, and thus
treatment effects can be expected to be
blunted, and the fact that at the end of
the trial 80% of the patients preferred the
burst protocol is also significant. More
recently, Deer et al20 published results of
the SUNBURST trial, which randomized
patients with refractory back and leg pain
to tSCS or burst stimulation. The trial was
conducted in two phases. First patients
were randomized to a 12-week period of
a given stimulation treatment, and then
switched to the other stimulation method
for the next 12 weeks. Thereafter, the
patients were allowed to choose their
preferred stimulation method and were
assessed every 6 months for two years.
The primary endpoint was change in VAS.
A total of 100 patients were randomized,
with 45 entering tSCS first followed
by burst, and 55 vice versa. At 12- and
24-week analyses, both non-inferiority
and superiority of burst stimulation as
compared to tSCS were established via
the primary endpoint of VAS reduction.
Secondary endpoint analyses revealed that
61.6% of patients were paresthesia-free

with burst compared to only 2.7% of
tSCS patients. While 78.1% of patients
were satisfied overall with both stimulation methods, 70.8% reported preferring
burst stimulation with lack of paresthesia
being the most common reason cited.
This preference was maintained at oneyear follow-up with 68.2% of patients
continuing to prefer burst therapy. Much
like high frequency stimulation, as the
clinical efficacy became clear, more questions emerged regarding mechanisms and
the impact of various stimulation parameters. One study21 randomized 15 patients
previously implanted with a burst-capable
device in the setting of FBSS to one of two
stimulation patterns: 1) 5 pulses delivered
at 500 Hz with a 1000 µsec pulse width, 40
times per second or 2) 5 pulses delivered at
1000 Hz, 1000 µsec pulse width, 40 times
per second. The amplitude, and thus the
total electrical dose delivered remained
the same. Clinical outcomes were not
significantly different.

DISCUSSION
Spinal cord stimulation was first put
into clinical practice in the 1960s for
an attempt at palliation in a patient with
terminal cancer pain.4 The momentum
behind its initial development was
the ubiquitous Gate Control Theory
put forth by Melzack and Wall. 3 While
generally accepted that this theory is
overly simplistic regarding the mechanism of action in the various spinal
cord stimulation techniques, it did
inspire generations of physicians and
scientists to develop new means of
tackling medically refractory chronic
pain syndromes. 22 Traditional, lowfrequency, suprathreshold tonic spinal
cord stimulation has been postulated
to work via several mechanisms. Most
commonly cited includes selective
activation of large, myelinated Aβ fibers
with subsequent inhibition of smaller,
pain-mediating Aδ and c fibers via
inhibitory interneurons. Other postulated contributors include dorsal horn
wide dynamic range neurons, thought to
develop a hypersensitivity in neuropathic
injury states with resultant increased
basal glutamate release and subsequent
glutamate:GABA imbalance. Supraspinal
mechanisms are also thought to be at
play although the exact brainstem-spinal

3

JHN Journal, Vol. 14 [2019], Iss. 1, Art. 5

circuitry activated by spinal cord stimulation remains largely theoretical. 22
Regardless of the inner workings of
the therapy, spinal cord stimulation has
proven to be an important development
in the management of an otherwise
frustrating patient population. Medical
management in chronic pain conditions
often fails and is associated with high
rates of narcotic medication use with
their associated complications. Futile
treatment regimens, although inexpensive in isolation, become expensive
when applied indefinitely, and costly
revision surgeries without clearly rectifiable structural or compressive pathology
are not only low yield, but very expensive
and potentially dangerous. Spinal cord
stimulation has provided an opportunity
to attain symptom relief, limit disability,
and improve patient productivity. And
although the upfront investment is
large, there is an increasing amount of
evidence suggesting that the long-term
cost-effectiveness profile is positive
and that spinal cord stimulation should
be considered earlier in the broader
treatment paradigm for chronic pain.1,2
With all of this said, spinal cord stimulation is certainly no panacea. One of
the most important limiting factors is
the requirement for a high-degree of
overlap between induced paresthesia
and the patient’s baseline pain. This
becomes a problem for patients that
can’t tolerate even mild paresthesia.
Furthermore, positional differences in
the intensity of elicited paresthesia have
been reported by some patients, and
occasionally even limit participation in
important day-to-day activities such as
driving. The requirement for paresthesia
overlap also makes the treatment of
axial symptoms particularly challenging,
as effective paresthesia coverage in this
region remains elusive even with today’s
technology. Given that chronic back pain
is one of the most common problems
in modern medical systems, achieving
efficient low back coverage is a priority
for next generation models.
With these challenges in mind, innovation in spinal cord stimulation has moved
towards paresthesia-free systems. Burst
patterns were developed as a means
of subthreshold stimulation that would
more closely resemble central nervous
system neuronal firing. Furthermore,
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simultaneous SCS/EEG studies have
suggested that burst stimulation impacts
cortical medial pain pathways, with De
Ridder et al 18 showing an effect on
connectivity involving dorsolateral
prefrontal, dorsal anterior cingulate,
and parahippocampal regions. In other
words, burst stimulation may impact
affective and attentional components
to pain in addition to pain transmission.
High-frequency, low-amplitude stimulation patterns have been developed
ranging up to 10,000 Hz. Again, the exact
mechanism of action of these systems
remains elusive, but several hypotheses
have been put forth, including production of a local sodium channel blockade
with inhibition of depolarization within
the dorsal columns, desynchronization of neuronal messaging from the
periphery, and inhibition of wide dynamic
range neuronal sensitization, among
others. 22 What is clearer is that the
clinical benefit has been demonstrated
in several randomized controlled trials,
most notably the SENZA trial14,15 where
both axial and limb pain response rates
approached 70% up to two years after
implantation. From a surgical perspective, the purely anatomic placement of
HF10 leads creates additional benefit
in terms of ease of placement for the
surgeon, without the need for uncomfortable wakeup testing for the patient
and likely shorter overall anesthesia time.
However, such systems are not without
their limits, as well. There is a certain
subset of patients that prefer paresthesias, ostensibly as a reassuring cue that
there is in fact a therapy being provided.
Furthermore, very high frequency systems
such as HF10 deliver much more charge
per second, which can lead to short
internal pulse generator (IPG) lifetime,
or in the case of rechargeable IPGs,
significant charging burden for the
patient. Additionally, the exact impact
of frequency, amplitude, and pulse
width, and thus total charge delivery, are
unclear and have not been systematically
accounted for in the available literature.
It is highly likely that simple frequency
modulation is not by itself responsible
for the clinical benefit of this technique,
and a clearer understanding of how
these parameters come together for
therapeutic effect will be critical if we are
to maximize the potential benefit.

Modern Spinal Stimulation

CONCLUSION
Chronic back pain remains a highly prevalent clinical problem in modern society.
This patient population has historically
been very challenging to treat. Spinal
cord stimulation has helped to bridge
the treatment gap in these patients, and
while progress so far has been encouraging, there remains much research to
be done to fully understand the mechanisms and potential therapeutic reach of
this modality.
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